T 0845/19 (Anti-PCSK9 antibodies/AMGEN) of 29.10.2020
- European Case Law Identifier
- ECLI:EP:BA:2020:T084519.20201029
- Date of decision
- 29 October 2020
- Case number
- T 0845/19
- Petition for review of
- -
- Application number
- 08798550.3
- IPC class
- A61K 45/06A61K 31/47A61P 3/06C12N 15/113A61K 31/405A61K 31/40A61K 39/395A61K 31/66A61K 31/22A61K 39/00A61K 31/366A61K 31/505C07K 16/40A61K 31/44
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
- Applicant name
- Amgen Inc.
- Opponent name
- Sanofi
Strawman Limited
Eli Lilly and Company
Sanofi-Aventis Deutschland GmbH/Sanofi-Aventis
Groupe S.A./Sanofi Winthrop Industries S.A.
Regeneron Pharmaceuticals, Inc. - Board
- 3.3.04
- Headnote
- -
- Relevant legal provisions
- -
- Keywords
- Main Request - Maintenence in amended form (yes)
- Catchword
- -
- Cited cases
- -
Order
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The case is remitted to the opposition division with the order to maintain the patent with the following claims and a description and drawings adapted thereto:
Claims 1 to 15 of the main request, filed as auxiliary request 7 with the patent proprietor's reply of 3 December 2019.